600566 济川药业
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入5,805,135-11.19%9,654,5378,996,3677,630,5106,164,974
减:营业总成本3,879,965-12.97%6,516,4586,620,7285,862,6874,725,475
    其中:营业成本1,204,1230.63%1,783,9931,537,4111,276,5641,130,254
               财务费用(205,391)20.60%(257,489)(85,763)(88,966)(48,074)
               资产减值损失------------
公允价值变动收益86,459456.47%14,604(7,316)114,55420,942
投资收益30,728-59.91%81,72466,20946,9781,366
    其中:对联营企业和合营企业的投资收益----2,457769675(245)
营业利润2,119,658-4.72%3,258,1362,423,4981,932,8261,468,965
利润总额2,233,498-1.15%3,297,0902,507,9211,950,4351,483,506
减:所得税费用326,1524.47%470,027336,202233,219206,294
净利润1,907,346-2.06%2,827,0632,171,7191,717,2161,277,212
减:非控股权益4,51740.18%4,282969(1,959)--
股东净利润1,902,830-2.13%2,822,7812,170,7501,719,1761,277,212

市场价值指针
每股收益 (元) *2.071-2.45%3.0802.4401.9401.530
每股派息 (元) *----1.3000.8800.6800.450
每股净资产 (元) *15.26712.92%14.48212.29910.1508.626
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容